Progress in gene therapy for chronic granulomatous disease

Area of Science:

• Immunology
• Molecular Biology
• Genetic Medicine

Background:

• Chronic granulomatous disease (CGD) is an inherited immune disorder characterized by defective leukocyte oxidase activity.
• This deficiency impairs the ability of phagocytes to kill ingested pathogens, leading to recurrent infections.

Purpose of the Study:

• To review the progress and potential of gene therapy for treating chronic granulomatous disease.
• To evaluate the efficacy of retroviral vector-mediated gene transfer in correcting the oxidase defect.

Main Methods:

• Utilized retrovirus vectors to deliver oxidase enzyme subunit cDNA into hematopoietic progenitors.
• Tested gene therapy in CGD mouse knockouts (X-linked gp91phox-deficient and autosomal recessive p47phox-deficient).
• Conducted a phase I clinical trial for ex vivo gene therapy in p47phox-deficient CGD patients.

Main Results:

• Gene therapy corrected oxidase activity in neutrophils derived from transduced progenitors in vitro.
• In CGD mouse models, gene therapy led to oxidase-normal neutrophils and increased resistance to bacterial and fungal infections.
• Phase I trial achieved prolonged, albeit low-level, production of oxidase-normal neutrophils in patients.

Conclusions:

• Gene therapy is a viable strategy for correcting the genetic defect in chronic granulomatous disease.
• Even transient production of autologous gene-corrected neutrophils may significantly augment host defense in CGD patients.
• Further development of gene therapy holds potential for managing chronic infections in CGD.